Novel Antigen Targets for Immunotherapy of Acute Myeloid Leukemia.

ABSTRACT: Acute myeloid leukemia (AML) was the first malignancy for which immunotherapy, in the form of allogeneic hematopoietic stem cell transplantation (allo-HSCT), was integrated into the standard of care. Allo-HSCT however is an imperfect therapy associated with significant morbidity and mortality while offering only incomplete prevention of AML clinical relapse. These limitations have motivated the search for AML-related antigens that might be used as more specific and effective targets of immunotherapy. While historically such investigations have focused on protein targets expressed uniquely in AML or at significantly higher levels than in normal tissues, this article will review recent discoveries which have identified a novel selection of potential antigen targets for AML immunotherapy, suc

SUBMITTER: Goswami M 

PROVIDER: S-EPMC6321986 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature